Wikipedia -WSS

Wikipedia

author：hotspot 2025-10-01 14:59:22 - browse：22596

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： As a primary care physician, here's how I hope to partner with AI

WSS

UnitedHealth argues against case alleging wrongful AI care denials

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Questions and answers about ramping up H5N1 bird flu vaccine

As a primary care physician, here's how I hope to partner with AI

Listen: More tumult at BIO & coercive care for sickle cell patients

Why health care costs have stayed mostly flat since 2010

focus

Wikipedia

focus

At least 13 dead in Texas as scorching temps continue

What STAT readers think about the FDA and patient advocacy

DIEP, the 'gold standard' of breast reconstruction, is under threat

Biogen joins immunology wave with $1.15 billion acquisition of HI

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Walensky prepares to leave CDC — and Congress — behind

Investigation reveals sickle cell patients pressured into sterilizations

Jerome Adams on the need for new antivirals for Covid

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

leisure time

Can sheer will power keep patients alive in their dying hours?

Eyeing GLP

CRISPR gene editing developments we’re watching in 2024

Can sheer will power keep patients alive in their dying hours?

Medicare drug price negotiation hasn't dried up venture capital

UnitedHealth argues against case alleging wrongful AI care denials

knowledge

entertainment

knowledge

focus